Jazz Pharmaceuticals
- Market cap
- 15.01B
- P/E (TTM)i
- 15.82
- P/Bi
- 3.13
- EPSi
- -5.84
- Div yieldi
- 0.00%
- 52W posi
- 74%
Anonymous reader poll. Unscientific, not investment advice.
Jazz Pharmaceuticals ended the session at 231.19, down 0.09%. Its market capitalisation is about 15.01B, the #1123 most valuable US-listed company we track. Trading at a P/E of 15.85, the stock is 75% below its own five-year norm of 62.90. Across 17 analysts the consensus rating is Buy, with an average price target of 303.06 (+31%). The shares sit 74% of the way up their 52-week range of 128.80 to 266.38.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 12% of the universe, above its 200-day average.
- Signal has read BUY for 6 months.
- Its last 3 Buy calls have averaged close to flat (-1%) three months out - no strong edge on this name specifically.
- Recent price momentum is +30.8% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 7.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation B
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 16.2x | Better than 60% |
| Forward P/E | 11.8x | Better than 75% |
| Price / Sales | 3.3x | Better than 45% |
| P/E vs own 5-yr range | 63rd pctl | Better than 47% |
Growth B
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 5.3% | Better than 45% |
| Net income CAGR (3Y) | 20.2% | Better than 74% |
| Free cash flow CAGR (3Y) | 14.0% | Better than 56% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 88.2% | Better than 97% |
| Operating margin | 12.1% | Better than 40% |
| Net margin | -8.3% | Better than 7% |
| Return on equity | -8.5% | Better than 9% |
| Return on invested capital | -2.1% | Better than 12% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -4.7% | Better than 42% |
| 6-month return | 23.6% | Better than 75% |
| 12-month return (ex latest month) | 79.4% | Better than 91% |
| Distance below 52-week high | 11.4% | Better than 71% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.9x | Better than 64% |
| Debt to assets | 46.5% | Better than 30% |
| Interest coverage | -2.2x | Better than 9% |
| Free cash flow / net income | 240.6% | Better than 87% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 28.4% | Better than 57% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 231.39
- Open
- 229.62
- Day range
- 227.00 - 235.54
- Avg price
- 232.16
- Volume
- 578.91K
- Turnover
- 134.40M
- Turnover ratei
- 0.92%
- Volume ratioi
- 0.71
- Amplitudei
- 3.69%
- 52-week rangei
- 128.80 - 266.38
Valuation
- P/Ei
- -39.59
- P/E (TTM)i
- 15.82
- P/Bi
- 3.13
- EPSi
- -5.84
- Book value / shi
- 73.97
- Net profit
- -379.10M
- Net assets
- 4.80B
Share structure
- Market cap
- 15.01B
- Float capi
- 14.56B
- Shares out
- 64.91M
- Float sharesi
- 62.98M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
13.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+17.33M net over the window
Short interest
- Shares short
- 4.68M
- % of floati
- 7.20%
- Days to coveri
- 7.22
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Jazz Pharmaceuticals (JAZZ)?
Jazz Pharmaceuticals last traded at 231.19. The quote on this page refreshes every few seconds while US markets are open.
What is Jazz Pharmaceuticals's market cap?
About 15.01B.
What is the P/E ratio of Jazz Pharmaceuticals?
The trailing twelve-month P/E is 15.82, below its own 5-year average of 62.90 — in the middle of its historical range (62.57% percentile). See the Valuation tab for the full history.
Does Jazz Pharmaceuticals pay a dividend?
Jazz Pharmaceuticals does not currently pay a regular dividend.
Is Jazz Pharmaceuticals a buy according to analysts?
The consensus of 17 analysts is a Buy rating, with an average 12-month price target of 303.06, which implies 31.1% upside from the current price. This is not investment advice.
What is Jazz Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Jazz Pharmaceuticals a B (Buy). Twelve-month momentum in the top 12% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 07:19:06 · For reference only, not investment advice and not tailored to your situation.